NCT01305486

Brief Summary

This will be an observational study designed to collect early, short- and long-term clinical outcomes of the XenMatrix™ Surgical Graft for complex ventral hernia repair. Subjects will be expected to attend follow up visits at 1, 6, 12, 18 and 24 months following surgery.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2010

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2010

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

December 22, 2010

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 28, 2011

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2011

Completed
Last Updated

January 15, 2013

Status Verified

January 1, 2013

Enrollment Period

9 months

First QC Date

December 22, 2010

Last Update Submit

January 14, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • To estimate the hernia recurrence rate of complex ventral hernias post repair with the XenMatrix™ Surgical Graft utilizing the component separation technique with several different tissue plane placements of the graft for up to 24 months post surgery.

    Any hernia which is identified or confirmed by the investigator in approximately the same position as the hernia repair during any follow up visit after a XenMatrix™ surgical graft has been placed will be considered a recurrent hernia.

    2 Years

Secondary Outcomes (4)

  • To assess perioperative, short-term and long-term complications in subjects with complex hernias repaired with XenMatrix™ Surgical Graft and component separation.

    2 Years

  • To assess the procedural time for XenMatrix™ Surgical Graft placement with component separation.

    Day 0

  • To assess changes in subject quality of life (QOL) post repair with a XenMatrix™ Surgical Graft with component separation.

    2 years

  • To assess clinical outcomes based on the tissue plane placement of the XenMatrix™ Surgical Graft.

    2 years

Study Arms (1)

XenMatrix

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects who are diagnosed with a ventral or incisional hernia that require a component separation repair with the use of a biological graft.

You may qualify if:

  • Be able to undergo study procedures.
  • Have signed an Informed Consent form (ICF).
  • Be diagnosed with a ventral or incisional hernia that cannot be closed primarily in the opinion of the investigator.
  • Requires a component separation repair with the use of a biological graft.

You may not qualify if:

  • Subject is participating in another device or drug study.
  • Subject has a life expectancy less than 4 years at the time of enrollment.
  • Any condition in the opinion of the investigator that would preclude the use of the XenMatrix™ Surgical Graft, or preclude the subject from completing the follow-up requirements.
  • Any subject with a defect the surgeon feels he/she cannot fully close.
  • Subjects with a BMI \> 50.
  • Subjects with connective tissue disorders.
  • Subjects with a history of cirrhosis.
  • Subjects with renal failure requiring dialysis.
  • Subjects on or suspected to be placed on chemotherapy or systemic immunosuppressive medications during any part of the study.
  • Transplant recipients.
  • Subjects taking corticosteroids for \>6 months (pre or post surgery).
  • Any bowel leak or infection that would preclude the use of the XenMatrix™ Surgical Graft in the opinion of the investigator.
  • The subject lives approximately 2 hours away from the study site and compliance with follow up requirements will be difficult in the opinion of the investigator.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Our Lady of the Lake Regional Medical Center

Baton Rouge, Louisiana, 70808, United States

Location

MeSH Terms

Conditions

Hernia

Condition Hierarchy (Ancestors)

Pathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Karl LeBlanc, MD

    Our Lady of the Lake Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 22, 2010

First Posted

February 28, 2011

Study Start

September 1, 2010

Primary Completion

June 1, 2011

Study Completion

June 1, 2011

Last Updated

January 15, 2013

Record last verified: 2013-01

Locations